Annual report [Section 13 and 15(d), not S-K Item 405]

Segment Information

v3.25.1
Segment Information
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment Information

Note 14. Segment Information

The Company is comprised of one reportable segment, the Company operations. As of December 31, 2024, the Company operations segment has not generated any product revenue since inception, as it does not yet have approved products for sale. However, the Company operations segment anticipates future revenue generation upon the successful development and commercialization of product candidates either independently or through partnerships.

The Company expects to primarily generate revenue in North America, with its long-lived assets also concentrated in this region, and manages its business activities on a consolidated basis. Decisions concerning the allocation of the Company’s resources are made by the Company’s Chief Operating Decision Maker (CODM), which is the Company’s Chief Executive Officer (CEO). The CODM views the Company’s operations as a single operating segment which is the business of discovering and developing products for individuals with serious and rare genetic skin diseases.

The Company’s significant segment expenses that are regularly provided to the CODM are related to:

•
Research and Development Expenses: These expenses include costs incurred in conducting research and development activities for the specific clinical trials including facilities costs, license fee and other costs incurred in connection with preclinical research and development activities. Research and development also encompass non-program specific costs such as salaries and stock – based compensation costs, third party consulting fees, and other related costs.
•
General and Administrative Expenses: These expenses include costs associated with the overall administration and management of the Company, including salaries and benefits for administrative personnel, professional service fees (e.g., accounting and legal services) and other office expenses.

The CODM assesses performance for the Company operations segment and decides how to allocate resources based on net income or loss that is also reported on the income statement as consolidated net income or loss and the measure of segment assets as reported on the balance sheet as total consolidated assets. Net income or loss is used to monitor budget versus actual results as well as assess the general performance of the segment in a given period.

The following table reconciles segment direct profit or loss to the Company’s consolidated results:

 

 

Year Ended December 31,

 

(in thousands)

2024

 

 

2023

 

Research and development:

 

 

 

 

 

QTORIN rapamycin for PC and GS

$

—

 

 

$

3,682

 

QTORIN rapamycin for microcystic LM

 

1,929

 

 

 

164

 

QTORIN rapamycin for microcystic LM - Government grant income

 

(141

)

 

 

—

 

QTORIN rapamycin for cutaneous VM

 

296

 

 

 

—

 

QTORIN rapamycin CMC

 

1,601

 

 

 

878

 

Non-program specific and unallocated research and development expenses:

 

 

 

 

 

Salaries and stock-based compensation

 

2,810

 

 

 

2,383

 

Consultants

 

1,040

 

 

 

1,229

 

Other

 

616

 

 

 

457

 

Total research and development

$

8,151

 

 

$

8,793

 

General and administrative:

 

 

 

 

 

Salaries and stock-based compensation

$

1,935

 

 

$

821

 

Consultants

 

2,961

 

 

 

605

 

Other

 

1,048

 

 

 

1,650

 

Total general and administrative

$

5,944

 

 

$

3,076

 

Loss from operations

$

(14,095

)

 

$

(11,869

)